Company Description
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases.
The company’s lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome.
It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; zaltenibart that is in phase 3 clinical trials for Paroxysmal nocturnal hemoglobinuria; in phase 2 clinical trial for the treatment complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder.
In addition, the company’s products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Immunostimulator Combination Therapies, and Oncotoxins and Immunomodulators for the treatment of various cancers.
Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
| Country | United States |
| Founded | 1994 |
| IPO Date | Oct 8, 2009 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 202 |
| CEO | Gregory Demopulos |
Contact Details
Address: The Omeros Building, 201 Elliott Avenue West Seattle, Washington 98119 United States | |
| Phone | 206 676 5000 |
| Website | omeros.com |
Stock Details
| Ticker Symbol | OMER |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001285819 |
| CUSIP Number | 682143102 |
| ISIN Number | US6821431029 |
| Employer ID | 91-1663741 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Gregory A. Demopulos M.D. | Co-Founder, Chairman, Chief Executive Officer and President |
| Peter B. Cancelmo J.D. | Vice President, General Counsel and Corporate Secretary |
| Dr. Pamela Pierce Palmer M.D., Ph.D. | Co-Founder |
| David J. Borges | Vice President of Finance, Chief Accounting Officer and Treasurer |
| Dr. George A. Gaitanaris M.D., Ph.D. | Chief Scientific Officer and Vice President of Science |
| Peter W. Williams | Vice President of Human Resources |
| Dr. Catherine A. Melfi Ph.D. | Chief Regulatory Officer and Vice President of Regulatory Affairs and Quality Systems |
| Nadia Dac | Vice President and Chief Commercial Officer |
| Dr. Andreas Grauer M.D. | Vice President and Chief Medical Officer |
| David W. Ghesquiere | Vice President and Chief Business Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 6, 2025 | 8-K | Current Report |
| Apr 30, 2025 | 10-K/A | [Amend] Annual report |
| Mar 31, 2025 | 10-K | Annual Report |
| Mar 31, 2025 | 8-K | Current Report |
| Feb 21, 2025 | SCHEDULE 13G/A | Filing |
| Feb 20, 2025 | 8-K | Current Report |
| Jan 16, 2025 | 8-K | Current Report |
| Dec 19, 2024 | 8-K | Current Report |
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Nov 13, 2024 | 8-K | Current Report |